Kailera Therapeutics, Inc. (NASDAQ:KLRA) Given Consensus Rating of “Moderate Buy” by Brokerages

Kailera Therapeutics, Inc. (NASDAQ:KLRA) has received an average rating of “Moderate Buy” from the eight research firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $42.75.

KLRA has been the subject of several research reports. TD Cowen began coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They set a “buy” rating and a $57.00 price objective for the company. Evercore began coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They issued an “outperform” rating on the stock. Weiss Ratings began coverage on Kailera Therapeutics in a report on Friday, August 14th. They set a “sell (d)” rating on the stock. William Blair initiated coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They issued an “outperform” rating for the company. Finally, JPMorgan Chase & Co. initiated coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They issued an “overweight” rating and a $30.00 price target for the company.

Institutional Trading of Kailera Therapeutics

A hedge fund recently bought a new position in Kailera Therapeutics stock. Wellington Management Group LLP purchased a new position in shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 2,919,110 shares of the company’s stock, valued at approximately $64,308,000. Wellington Management Group LLP owned 2.25% of Kailera Therapeutics as of its most recent SEC filing.

Kailera Therapeutics Stock Performance

Shares of KLRA opened at $18.32 on Thursday. Kailera Therapeutics has a 52-week low of $16.39 and a 52-week high of $28.23. The firm has a market cap of $2.38 billion and a PE ratio of -0.01. The business’s fifty day simple moving average is $19.36.

Kailera Therapeutics (NASDAQ:KLRA) last issued its earnings results on Wednesday, August 12th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.35). On average, sell-side analysts predict that Kailera Therapeutics will post -3.89 EPS for the current year.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.